Bristol Myers, J&J Stop Late-Stage Trial After Heart Disease Treatment Falls Short
By Connor Hart
Bristol Myers Squibb and Johnson & Johnson are halting a late-stage trial of their experimental heart-disease drug after an interim analysis found the treatment was unlikely to succeed.
The companies said Friday that an independent committee recommended stopping the phase 3 trial after concluding that the drug, milvexian, was unlikely to meet the study's main goal of reducing major cardiovascular events in patients recovering from acute coronary syndrome.
Shares of Bristol Myers slipped 5.4% to $45.99 in premarket trading. Johnson & Johnson's stock was roughly flat at $195.27.
Despite the setback, the companies said no new safety concerns related to milvexian were identified, and that they still see promise for the drug in other settings. Two other ongoing Phase 3 studies of the drug will continue as planned, with results expected in 2026.
"Together with Johnson & Johnson, we remain confident in the potential of milvexian to redefine anticoagulant therapy and provide patients and clinicians a new therapeutic option," said Roland Chen, senior vice president of drug development, immunology and cardiovascular medicines at Bristol Myers.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 14, 2025 07:53 ET (12:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
Your 7-Figure Retirement Fund Might Not Stretch As Far As You Think. Here’s How to Change That
This Wide-Moat Stock Is Still a Buy After Its Rally
These 15 Stocks Destroyed the Most Shareholder Value Over the Past Decade
3 Stocks to Sell and 3 Stocks to Buy in August
United States